Hainan Huluwa Pharmaceutical Group announcement, the company and its subsidiaries have received a cumulative government subsidy related to income from May 31, 2024 to the date of this announcement, amounting to RMB 10.6863 million (unaudited), accounting for 10.03% of the net income attributable to the owners of the parent company in 2023. The above subsidies are all related to income, and are expected to have a certain impact on the company's profit in 2024. Specific accounting treatment shall be subject to the annual audit confirmation by the accountant.